Back to Newsroom

Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA

BETHESDA, Md., Oct. 9, 2014 (GLOBE NEWSWIRE) — Sucampo Pharmaceuticals, Inc.(Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that Sucampo, R-Tech Ueno, Ltd. (RTU), Takeda Pharmaceutical Company Limited (Takeda) and certain affiliates of Takeda have entered into a settlement and license agreement with Anchen Pharmaceuticals, Inc., Par Pharmaceutical, Inc., and Par Pharmaceutical Companies, Inc., (collectively, Par) that resolves patent litigation in the United States (U.S.) related to Sucampo’s AMITIZA® (lubiprostone) 8 mcg and 24 mcg soft gelatin capsules.

Click here to read more